Modelling adrenal steroid profiles to inform monitoring guidance in congenital adrenal hyperplasia

Lawrence, Neil R., Dawson, Jeremy, Lang, Zi-Qiang, Prete, Alessandro, Baranowski, Elizabeth S., Schiffer, Lina, Taylor, Angela E., Brac de la Perrière, Aude, Hirschberg, Angelica Lindén, Juul, Anders, Merke, Deborah P., Newell-Price, John, Rees, D. Aled ORCID: https://orcid.org/0000-0002-1165-9092, Reisch, Nicole, Stikkelbroeck, Nike, Touraine, Philippe A., Krone, Nils, Keevil, Brian, Collins, Gary S., Arlt, Wiebke and Ross, Richard J.M. 2025. Modelling adrenal steroid profiles to inform monitoring guidance in congenital adrenal hyperplasia. EBioMedicine 116 , 105749. 10.1016/j.ebiom.2025.105749

PDF - Published Version Download (3MB)

Abstract

Background There is no consensus on how to monitor adrenal androgens in Congenital Adrenal Hyperplasia (CAH). Methods Modelling of serum and salivary steroid profiles in healthy participants and patients with CAH randomised to either standard treatment or modified-release hydrocortisone hard capsules (MRHC). Findings Changes in serum 17-hydroxyprogesterone (17OHP) and androstenedione (A4) paralleled each other in healthy participants (n = 19) and patients with CAH (n = 122). However, healthy participants had similar absolute levels of 17OHP and A4 whereas patients with CAH had proportionally higher levels of 17OHP. Cross-correlation showed no lag between serum 17OHP and A4. In CAH, Bayesian multiple change point analysis converged on a 17OHP of 4.5 nmol/l below which in proportion to 17OHP the A4 is lower. Patients on standard treatment had a morning peak in 17OHP and A4 whereas patients on MRHC had relatively flat profiles. Salivary androgens including 11-ketotestosterone correlated with serum 17OHP and A4 in female patients (r = 0.7 to 0.9). Interpretation In CAH, elevated 17OHP drives the production of A4. High A4 reflects poor control, but low A4 does not indicate overtreatment. Accepting 17OHP is higher than A4, both measurements give similar reflection of control, and a 17OHP <38 nmol/l (1250 ng/dl) was associated with an A4 in the normal range <5 nmol/l (143 ng/dl) in 95% of patients and in clinical trials was used to define good control. On MRHC, which controls androgen levels over 24 h, a single sample of 17OHP and/or A4 can be used to monitor control. Salivary measurements reflect similar results to serum. Funding Diurnal; MRC; NIH; NIHR.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Additional Information:	License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by-nc-nd/4.0/, Start Date: 2025-04-25
Publisher:	Elsevier
ISSN:	2352-3964
Date of First Compliant Deposit:	9 June 2025
Date of Acceptance:	25 April 2025
Last Modified:	09 Jun 2025 10:15
URI:	https://orca.cardiff.ac.uk/id/eprint/178900

Actions (repository staff only)

Edit Item